Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.

Selvarajah D, Webster J, Ross R, Newell-Price J.

Eur J Endocrinol. 2005 Apr;152(4):569-74.

2.
3.

Cabergoline treatment of acromegaly: a preliminary dose finding study.

Jackson SN, Fowler J, Howlett TA.

Clin Endocrinol (Oxf). 1997 Jun;46(6):745-9.

PMID:
9274706
4.

Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.

Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM.

J Clin Endocrinol Metab. 2009 Apr;94(4):1255-63. doi: 10.1210/jc.2008-1420. Epub 2009 Jan 21.

PMID:
19158203
5.

In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.

Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.

Clin Endocrinol (Oxf). 2001 Apr;54(4):469-77.

PMID:
11318782
6.

The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.

Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA.

Clin Endocrinol (Oxf). 2005 Mar;62(3):282-8.

PMID:
15730408
7.

Medical therapy for acromegaly.

Newman CB.

Endocrinol Metab Clin North Am. 1999 Mar;28(1):171-90. Review.

PMID:
10207690
8.

Remission of acromegaly following long-term therapy with cabergoline: report of two cases.

Verhelst JA, Abrams PJ, Abs R.

Pituitary. 2008;11(1):103-7.

PMID:
17530416
9.

Clinical use of cabergoline as primary and adjunctive treatment for acromegaly.

Moyes VJ, Metcalfe KA, Drake WM.

Eur J Endocrinol. 2008 Nov;159(5):541-5. doi: 10.1530/EJE-08-0306. Epub 2008 Aug 15.

10.

Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.

Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A.

Pituitary. 1999;1(2):115-20.

PMID:
11081189
11.

Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.

Jallad RS, Bronstein MD.

Neuroendocrinology. 2009;90(1):82-92. doi: 10.1159/000218323. Epub 2009 May 8.

PMID:
19439914
12.

Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I.

Scacchi M, Carzaniga C, Vitale G, Fatti LM, Pecori Giraldi F, Andrioli M, Cattaneo A, Cavagnini F.

J Endocrinol Invest. 2011 Oct;34(9):e291-5. doi: 10.3275/7802. Epub 2011 Jun 21.

PMID:
21697649
13.

Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?

Cozzi R, Attanasio R, Grottoli S, Pagani G, Loli P, Gasco V, Pedroncelli AM, Montini M, Ghigo E.

J Endocrinol Invest. 2004 Dec;27(11):1040-7.

PMID:
15754736
14.

A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.

Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G.

Eur J Endocrinol. 1999 Sep;141(3):267-71.

15.

Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.

Howlett TA, Willis D, Walker G, Wass JA, Trainer PJ; UK Acromegaly Register Study Group (UKAR-3).

Clin Endocrinol (Oxf). 2013 Nov;79(5):689-99. doi: 10.1111/cen.12207. Epub 2013 Apr 24.

PMID:
23574573
16.

Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.

Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, van der Lely AJ.

Drugs. 2009 Nov 12;69(16):2207-26. doi: 10.2165/11318510-000000000-00000. Review.

PMID:
19852525
17.

Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy.

Ayuk J, Stewart SE, Stewart PM, Sheppard MC; European Sandostatin LAR Group.

Clin Endocrinol (Oxf). 2004 Mar;60(3):375-81.

PMID:
15009004
18.

Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.

Mattar P, Alves Martins MR, Abucham J.

Neuroendocrinology. 2010;92(2):120-7. doi: 10.1159/000317314. Epub 2010 Aug 25.

PMID:
20802256
19.

How effective are current therapies for acromegaly?

Freda PU.

Growth Horm IGF Res. 2003 Aug;13 Suppl A:S144-51. Review.

PMID:
12914744
20.

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.

Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B; Lanreotide Acromegaly Study Group.

Clin Endocrinol (Oxf). 2008 Aug;69(2):299-305. doi: 10.1111/j.1365-2265.2008.03208.x. Epub 2008 Jan 31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk